Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Titel:
Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial
Auteur:
Clarke, N.W. Ali, A. Ingleby, F.C. Hoyle, A. Amos, C.L. Attard, G. Brawley, C.D. Calvert, J. Chowdhury, S. Cook, A. Cross, W. Dearnaley, D.P. Douis, H. Gilbert, D. Gillessen, S. Jones, R.J. Langley, R.E. MacNair, A. Malik, Z. Mason, M.D. Matheson, D. Millman, R. Parker, C.C. Ritchie, A.W.S. Rush, H. Russell, J.M. Brown, J. Beesley, S. Birtle, A. Capaldi, L. Gale, J. Gibbs, S. Lydon, A. Nikapota, A. Omlin, A. O'Sullivan, J.M. Parikh, O. Protheroe, A. Rudman, S. Srihari, N.N. Simms, M. Tanguay, J.S. Tolan, S. Wagstaff, J. Wallace, J. Wylie, J. Zarkar, A. Sydes, M.R. Parmar, M.K.B. James, N.D.